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Chronic inflammation has been associated with an increased risk of several human malig-
nancies, a classic example being gastric adenocarcinoma (GC). Development of GC is
known to result from infection of the gastric mucosa by Helicobacter pylori, which initially
induces acute inflammation and, in a subset of patients, progresses over time to chronic
inflammation, gastric atrophy, intestinal metaplasia, dysplasia, and finally intestinal-type
GC. Germ-line encoded receptors known as pattern-recognition receptors (PRRs) are crit-
ical for generating mature pro-inflammatory cytokines that are crucial for both Th1 and
Th2 responses. Given that H. pylori is initially targeted by PRRs, it is conceivable that
dysfunction within genes of this arm of the immune system could modulate the host
response against H. pylori infection, and subsequently influence the emergence of GC. Cur-
rent evidence suggests thatToll-like receptors (TLRs) (TLR2,TLR3,TLR4,TLR5, andTLR9),
nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) (NOD1, NOD2, and
NLRP3), a C-type lectin receptor (DC-SIGN), and retinoic acid-inducible gene (RIG)-I-like
receptors (RIG-I and MDA-5), are involved in both the recognition of H. pylori and gastric
carcinogenesis. In addition, polymorphisms in genes involved in theTLR (TLR1,TLR2,TLR4,
TLR5, TLR9, and CD14) and NLR (NOD1, NOD2, NLRP3, NLRP12, NLRX1, CASP1, ASC,
and CARD8 ) signaling pathways have been shown to modulate the risk of H. pylori infec-
tion, gastric precancerous lesions, and/or GC. Further, the modulation of PRRs has been
suggested to suppress H. pylori -induced inflammation and enhance GC cell apoptosis,
highlighting their potential relevance in GC therapeutics. In this review, we present current
advances in our understanding of the role of the TLR and NLR signaling pathways in the
pathogenesis of GC, address the involvement of other recently identified PRRs in GC, and
discuss the potential implications of PRRs in GC immunotherapy.
Keywords: stomach neoplasm, Helicobacter pylori, inflammation, pattern-recognition receptors,Toll-like receptors,
NOD-like receptors, genetic polymorphism, therapeutics
INTRODUCTION
Of the three main types of stomach cancer, gastric adenocarci-
noma (GC), non-Hodgkin’s lymphoma, and gastrointestinal stro-
mal tumors, approximately 95% are GC, which remains one of
the most commonly diagnosed cancers in the world (1). In 2012,
stomach cancer was the fifth most common cancer worldwide,
with 952,000 new cases diagnosed, accounting for 6.8% of the
total cancer cases (1). Furthermore, it is the third leading cause
of cancer-related deaths worldwide, accounting for 8.8% of total
deaths from cancer, with 5-year relative survival rates lower than
30%, except in Japan where mass screening has been undertaken
for several years (2).
Gastric cancer is a heterogeneous pathology with respect
to anatomical location and histological subtypes (Figure 1A).
In relation to location, GC may occur in the cardia or non-
cardia region of the stomach. Cardia GC has been associated
with gastro-esophageal reflux, Helicobacter pylori infection, and
atrophic gastritis, male gender, smoking, and diet (3). Epidemi-
ological studies assessing the worldwide incidence of GC by
anatomical location have shown an increase in the incidence
of cardia GC, however, in high GC risk areas, non-cardia GC
remains the most frequent pathology (4). Further, even though
cardia and non-cardia GC have been considered etiologically
different phenomena, it has been demonstrated that cancer of
the cardia among individuals from areas with a high risk of
GC represents a subset of cardia GC that is associated with H.
pylori-related atrophic gastritis and resembles non-cardia GC
pathogenesis (5, 6).
According to the Lauren Classification, non-cardia GC has been
further subdivided into the two histological variants intestinal-
type and diffuse-type. Intestinal-type GC is characterized by the
formation of gland-like structures, distal stomach localization, and
a predilection for older individuals. It is also more frequent in
males (2:1 ratio) and in subjects of lower socioeconomic status
(10). This type of GC is often preceded by a precancerous phase
that starts with the transition of normal mucosa into multifocal
atrophic gastritis. This initial histological alteration is followed
by intestinal metaplasia, dysplasia, and finally adenocarcinoma
(11). On the other hand, diffuse-type GC is poorly differentiated,
affects younger individuals, and has been highly associated with
genetic susceptibility (the variant hereditary diffuse GC, which
is associated with germ-line mutations in CDH1, a gene encoding
E-cadherin) (12, 13). Additionally, it is not associated with the for-
mation of precancerous lesions and has been found to affect the
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FIGURE 1 | Gastric cancer classification and etiology. (A) Stomach
cancer comprises gastric adenocarcinoma (GC), non-Hodgkin lymphomas,
including mucosa-associated lymphoid tissue (MALT) lymphoma, and the
rare gastrointestinal stromal tumors (GIST), leiomyosarcoma, and carcinoid
tumors. The most common type, GC, has been classified as cardia and
non-cardia GC according to anatomical location. Cardia GC is divided into
two different etiological entities, esophageal-like cardia GC, which is
associated with gastro-esophageal reflux, smoking, and diet, and is frequent
in areas with a low risk of GC and distal stomach-like cardia GC, which is
associated with the presence of H. pylori and gastric atrophy, and is the
most frequent cardia GC variant in areas with a high risk of GC. Non-cardia
GC is further subdivided into two histological variants called intestinal-type
and diffuse-type GC. Intestinal-type GC, according to the widely accepted
Correa’s cascade (7), is a biological continuum that commences as chronic
gastritis and progresses to atrophic gastritis, intestinal metaplasia,
dysplasia, and finally, GC. *Stomach cancer subtypes that have been
associated with Helicobacter pylori infection. (B) H. pylori infection causes
chronic inflammation of the gastric mucosa of all infected individuals, and in
combination with host and environmental factor, leads to the development
of GC in a subset of infected individuals (1–3%). In these subjects,
inflammation represents the seventh hallmark of cancer and an enabling
characteristic that facilitates the acquisition of the other established
hallmarks that collectively dictate malignant growth (tissue
invasion/metastasis, limitless replicative potential, sustained angiogenesis,
evasion of programed-cell death (apoptosis), self-sufficiency in growth
signals, and insensitivity to growth-inhibitory signals) (8, 9).
entire surface of the stomach. This type of GC is present equally
between the two sexes and is associated with a worse prognosis in
comparison to intestinal-type GC (10, 12).
Most GC cases are sporadic and arise due to the combina-
tion of a permissive environment interacting with a susceptible
host. Several factors that contribute to the development of GC
have been identified; these include bacterial (H. pylori), host, and
environmental factors (12).
Helicobacter pylori is a Gram-negative bacterium that infects
nearly 50% of the human population (14). In the gastric mucosa,
the majority of Helicobacter pylori are found within the mucus
layer but they can also be attached to epithelial cells leading to the
maintenance, spread, and severity of the infection (15). H. pylori
infection has been associated with the development of a range
of diseases, including peptic ulcer disease (10%), non-cardia GC
(1–3%), and gastric mucosa-associated lymphoid tissue (MALT)
lymphoma (<0.1%) (14, 16–18). Furthermore, this bacterium has
been associated with three distinct phenotypes in the infected
host: (1) a corpus-predominant gastritis, which has the potential
to lead to atrophic gastritis, hypochlorhydria, and to the devel-
opment of GC; (2) a duodenal ulcer phenotype in which an
antrum-predominant gastritis leads to increased gastric acid secre-
tion; and (3) a benign phenotype in which the bacterial infection
causes a mild mixed gastritis that has a minor effect on gastric acid
production (19).
Helicobacter pylori infection is transmitted by direct human-
to-human transmission, via either the oral–oral route, fecal–oral
route, or both (14). H. pylori is acquired early in life, the majority
of individuals being infected before the age of 10 years with close
family members being a common source of infection (20–22).
It has been postulated that early acquisition of infection might
be associated with the broad pathological spectrum associated
with H. pylori infection and the highly persistent GC incidence
rates in genetically susceptible populations who have migrated to
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developed countries. In the absence of antibiotic therapy, H. pylori
infection generally persists for life (23).
Natural colonization by H. pylori is restricted to humans, pri-
mates, and domestic animals such as cats (23–25). H. pylori is
considered to be the dominant microorganism in the human stom-
ach as the majority of bacteria cannot survive in the low gastric pH
(26). Several other factors make the human stomach an unfavor-
able environment for bacterial colonization including peristalsis,
poor nutrient availability, and host innate and adaptive immu-
nity (23). The ability of H. pylori to survive and colonize the
stomach relates to a number of mechanisms. Most importantly
H. pylori, unlike other bacteria, produces large amounts of the
enzyme urease, which hydrolyzes urea to ammonia, which sub-
sequently interacts with hydrogen ions in the stomach to form
ammonium (27, 28). In addition, H. pylori is able to regulate
gene expression in response to changes in pH (29). Further, H.
pylori expresses multiple paralogous outer membrane proteins,
including the blood-group antigen-binding adhesin (BabA), the
sialic-acid binding adhesin (SabA), and the outer inflammatory
protein (OipA), which appear to bind to receptors on the surface
of gastric epithelial cells, which reduces the rate of bacterial elim-
ination as a result of peristalsis (30, 31). H. pylori counteracts the
lack of nutrients by inducing tissue inflammation and using spe-
cific systems that facilitate the transport and uptake of nutritional
resources (23). In addition, H. pylori has been reported to produce
antibacterial peptides that might decrease competition from other
microorganisms (32).
Further, a number of other factors have been shown to help
H. pylori evade the host immune system. For example, the vac-
uolating cytotoxin (VacA) produced by some strains of H. pylori
has been shown to inhibit T-cell proliferation as well as antigen
presentation by B cells and to alter the normal functions of CD8+
T cells, mast cells, and macrophages (33–36). In addition, gamma-
glutamyl transpeptidase, another immunosuppressive factor of
H. pylori, has been associated with inhibition of T-cell prolifer-
ation by induction of a cell cycle arrest in the G1 phase (37).
Furthermore, H. pylori has been shown to use arginase to down-
regulate the production of inducible nitric oxide synthase by
macrophages (38).
The fact that more than one H. pylori strain can colonize the
gastric mucosa provides the opportunity for H. pylori to acquire
new genetic sequences and to undergo recombination events (23).
One of the most remarkable differences among H. pylori strains is
the presence or absence of a 40-kb DNA insertion element known
as the cytotoxin-associated gene pathogenicity island (cag PAI)
(39). This region contains between 27 and 31 genes flanked by
31-bp repeats and encodes the most widely investigated H. pylori
virulence factor, the cytotoxin-associated antigen A (CagA) (40,
41). H. pylori strains expressing CagA represent 60–70% of West-
ern strains and approximately 100% of East Asian strains (39,
42). CagA is a 120- to 140-kDa protein that is translocated into
host cells through a type IV secretion system following attach-
ment to gastric epithelial cells (43). Following translocation, CagA
is tyrosine phosphorylated at the EPIYA (glutamate–proline–
isoleucine–tyrosine–alanine) motifs by members of the host cell
kinase families known as proto-oncogene proteins Abl and Src
(18). In Western populations strains, EPIYA-A, EPIYA-B, and vary-
ing numbers of EPIYA-C motifs have been reported, while in H.
pylori strains from East Asian populations, EPIYA-A and EPIYA-
B with EPIYA-D motifs, are found (44). Both phosphorylated
and non-phosphorylated CagA result in alterations in the gastric
epithelium including: (1) the activation of the protein tyrosine
phosphatase, non-receptor type 11 (SHP-2), (2) alterations in cell
scattering and proliferation, (3) alterations in cell structure and
cell motility, (4) perturbation of epithelial cell differentiation and
polarity, (5) alteration of tight junctions, and (6) aberrant activa-
tion of β-catenin (45–47). Furthermore, numerous studies have
shown that cag PAI-positive H. pylori strains are associated with
an increased risk of gastric diseases including peptic ulcer dis-
ease, premalignant gastric lesions and GC (48–51). Further details
of the interplay between H. pylori virulence factors and gastric
epithelial cells and GC, can be found in an excellent review by
Posselt et al. (44).
In the last two decades, a large number of epidemiological stud-
ies have established the association between H. pylori and the
subsequent risk of developing both intestinal-type and diffuse-
type GC (52–57). This finding has been consistent among different
populations. For example, in the study by Parsonnet et al. (57),
conducted in Caucasian,African-American, and Asian individuals,
subjects infected with H. pylori who had antibodies against CagA
were shown to be more likely than uninfected subjects to develop
both intestinal-type and diffuse-type GC (OR: 5.1, 95% CI: 2.1–
12.2 and OR: 10.1, 95% CI: 2.2–47.4, respectively). Consistently,
a further study conducted in a Japanese population showed that,
although the association was stronger in cases with intestinal-type
GC (OR: 3.2, 95% CI: 1.8–5.8), there was also a positive associ-
ation between H. pylori infection and diffuse-type GC (OR: 3.0,
95% CI: 1.0–8.8) (53). Further, a study conducted in a Spanish
population showed no differences in H. pylori infection between
the two GC histological subtypes (58). Similarly, a recent study in
German individuals showed that H. pylori prevalence was com-
parable in patients with intestinal-type (82.1%) and diffuse-type
(77.9%) GC (59).
Interestingly, more recent studies, assessing H. pylori infection
through Western blot (CagA) for the detection of past infection,
have shown an unprecedented association between H. pylori and
GC that can be explained by a reduction of the misclassification
that might take place when samples are analyzed with the enzyme-
linked immunosorbent assay (ELISA) alone (60, 61). For example,
Ekstrome et al. (60) conducted a population-based study, com-
prising 298 GC patients and 244 controls, in which the OR for
H. pylori infection among non-cardia GC was 21.0 (95% CI: 8.3–
53.4). Further, Siman et al. (61) showed that H. pylori significantly
increased the risk of non-cardia GC showing an OR of 17.8 (95%
CI: 4.2–74.8).
While H. pylori infection has been established as the most
important risk factor for GC and was classified as a class 1 car-
cinogen by the World Health Organization in 1994, the etiology of
GC also involves host and environmental factors. This is evidenced
by the fact that only 1–3% of H. pylori-infected patients develop
GC, and that progression to GC in some subjects occurs even after
eradication of the bacterium (18).
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Given that H. pylori is initially targeted by germ-line encoded
receptors known as pattern-recognition receptors (PRRs), it is
conceivable that dysfunction within genes of this arm of the
immune system would affect the magnitude and direction of the
host inflammatory response against the infection, resulting in an
increased risk of GC development. Recent studies clearly show
that PRRs are critical for generating mature pro-inflammatory
cytokines that are crucial for both Th1 and Th2 responses dur-
ing H. pylori infection, and these immune responses have been
directly associated with gastric immunopathology. In this review,
we present current advances in the understanding of the role of
PRRs, mainly the Toll-like receptor (TLR) and nucleotide-binding
oligomerization domain (NOD)-like receptor (NLR) signaling
pathways, in the pathogenesis of GC, and discuss future directions
for continued research in this area. In the first section, we highlight
the relevance of inflammation in GC. In subsequent sections, we
address new developments in the TLR and NLR signaling path-
ways in GC, the role of other PRRs in GC, and the new frontier of
therapeutic application of these concepts.
INFLAMMATION IN GASTRIC CANCER
It is well established that most cancer cell genotypes are the man-
ifestation of six essential alterations in cell physiology that collec-
tively dictate malignant growth: (1) self-sufficiency in growth sig-
nals, (2) insensitivity to growth-inhibitory signals, (3) evasion of
programed-cell death (apoptosis), (4) limitless replicative poten-
tial, (5) sustained angiogenesis, and (6) tissue invasion/metastasis
(8). Recently, inflammation has been considered the seventh hall-
mark of cancer and an enabling characteristic that facilitates the
acquisition of the other hallmarks (Figure 1B). Inflammation ini-
tiated by innate immune cells, mainly macrophage subtypes, mast
cells, myeloid progenitors, and neutrophils (62–65), designed to
fight infections and heal wounds, can instead result in uninten-
tional support of multiple cancer hallmark functions, thereby
manifesting the widely accepted tumor-promoting consequences
of inflammatory responses (9). In addition, active evasion by can-
cer cells from attack and elimination by immune cells, mainly
CD8+ cytotoxic T lymphocytes, CD4+ Type 1 helper T cells, and
natural killer (NK) cells, highlights the dual role of an immune
system that both antagonizes and promotes cancer development
and progression (9).
In the context of tumor enhancement, it has been proposed
that once inflammation is initiated, tissue integrity is compro-
mised leading to the multistage process of carcinogenesis by
altering targets and pathways that are pivotal for normal tissue
homeostasis (66). The mechanisms that are connected to these
alterations include production of mutagenic reactive oxygen and
nitrogen species as well as synthesis of cytokines and growth
factors that favor tumor cell growth (67). In addition, inflamma-
tion provides a source of other bioactive molecules to the tumor
microenvironment, including survival factors that limit cell death,
pro-angiogenic factors, extracellular matrix-modifying enzymes
that facilitate angiogenesis, invasion, and metastasis, and inductive
signals that lead to activation of the epithelial–mesenchymal tran-
sition (a developmental regulatory program that enables epithelial
cells to invade, resist apoptosis, and disseminate) (9). Interest-
ingly, inflammation can be considered a “perigenetic alteration” of
cancer cells because it may promote growth, expansion, and inva-
sion of tumors even without the involvement of further genetic
mutations or epigenetic alterations (68).
In 1988, Correa proposed a human model of intestinal-type
gastric carcinogenesis (7). The model hypothesized a sequence of
events progressing from acute inflammation to chronic inflamma-
tion, to atrophy, to intestinal metaplasia, to dysplasia, to carcinoma
in situ, and finally to invasive GC. A subsequent study by Correa
evaluated the gastric precancerous process in a Colombian popu-
lation (7). The results of this cross-sectional study led to the widely
accepted conclusion that the severity of atrophy correlates with the
prevalence of metaplasia and that the severity of metaplasia corre-
lates with the prevalence of dysplasia, suggesting that the process
is indeed a biological continuum (69).
Given that inflammation is a hallmark of gastric carcino-
genesis, polymorphisms in genes encoding pro-inflammatory
cytokines/chemokines have been the focus of much research in
recent years. To date, polymorphisms in the interleukin (IL)-1
family genes have been the most widely studied, including poly-
morphisms in IL1A, IL1B, and IL1RN that encode IL-1α, IL-1β,
and their endogenous receptor antagonist IL-1RA, respectively. In
particular, IL-1β, a potent endogenous pyrogen and an important
component in the development of Th2-mediated immunity (70,
71), has been associated with lipid peroxidation, DNA damage,
inhibition of gastric acid secretion, increased H. pylori coloniza-
tion, and induction of gastric atrophy and dysplasia in the presence
or absence of H. pylori (72). Global meta-analyses have shown that
the IL1B-511 T allele is significantly associated with an increased
risk of developing GC in Caucasians but not Asians or Mesti-
zos (73, 74). Furthermore, IL-1 receptor signaling is known to
induce the production of genes that not only stimulate tumor
growth but are also involved in angiogenesis and metastasis such
as matrix metalloproteinases, basic fibroblast growth factor, vas-
cular endothelial growth factor, vascular cell adhesion molecule 1,
intercellular adhesion molecule 1, monocytic chemotactic protein
1, and CXCL-2 (75). To date, only one study has addressed the
role of IL1R1 (also known as CD121A) in GC and H. pylori infec-
tion. The study, conducted in a Caucasian population, showed
an increased risk of H. pylori infection in those harboring the
IL1R1 Hinfl A allele (OR: 2.01, P-value: 0.009) but failed to show
an association with GC (76). In addition, a recent meta-analysis
on the endogenous receptor antagonist IL-1RA has shown the
IL1RN*22 genotype to increase the risk of gastric precancerous
lesions, supporting a role for this polymorphism in the early stages
of gastric carcinogenesis (OR: 2.27, 95% CI: 1.40–3.70) (77). A fur-
ther meta-analysis that included 39 case–control studies, showed
statistically significant associations between the IL1RN*22 geno-
type and both intestinal-type and diffuse-type GC, showing ORs
of 1.83 and 1.72, respectively (78). Further examples of polymor-
phisms in pro-inflammatory cytokines/chemokines that play an
essential role promoting inflammation in the context of gastroin-
testinal carcinogenesis are IL-4 (IL4-590C/T and -168T/C) (79),
IL-6 (IL6-174 G/C) (80–82), IL-8 (IL8-251 A/T, +396 T/G, and
+781 C/T) (79, 83), IL-10 (IL10-1082 A/G,−819 C/T, and −592
C/A) (84–86), IL-12 (IL12A-701 C/A, −798 T/A, +277 G/A, and
−504 T/G) (87), IL-17 (IL17 -197 G/A and+7488 T/C) (79), IL-18
(IL18-137 G/C) (88), and TNF-α (TNFA −238 G/A, −308 G/A,
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and −857 C/T) (89). In addition to this, a recent comprehensive
review on this topic recommended the investigation of other poly-
morphisms in IL1B (3954 C/T and −1473G/C), IL4 (–168T/C),
IL6 (572 G/C and 597 G/A), and IL17 (+7488A/G and−197G/A),
given their potential relevance in GC (79).
While extensive evidence supports the important role of pro-
inflammatory cytokines/chemokines in gastric carcinogenesis,
given that PRRs, mainly TLRs and NLRs, are important mod-
ulators of intestinal epithelial barrier function, epithelial repair,
and immune homeostasis in the gastrointestinal tract (90), and
that signal transduction from these receptors converges upon
a common set of signaling molecules, including the activation
of the transcription factors nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) and the activator pro-
tein 1 (AP-1) that lead to the production of pro-inflammatory
cytokines/chemokines (e.g., IL-1α, IL-1β, IL-6, IL-8, IL-10, and
TNF-α) as well as members of the interferon (IFN) regulatory
transcription factor family that mediate type I IFN-dependent
responses, defects in PRRs function could be even more important
than defects in pro-inflammatory cytokines/chemokines per se in
the instauration of an inflammation-related disorder such as GC.
PATTERN-RECOGNITION RECEPTORS IN GASTRIC CANCER
Innate immunity refers to responses that do not require previ-
ous exposure to an immune stimulus and represents the first line
of host defense in the response to pathogens. PRRs are part of
the innate immune system and are pivotal for the detection of
invariant microbial motifs. PRRs have been divided into five dis-
tinct genetic and functional clades: TLRs, NLRs, C-type lectin
receptors (CLRs), retinoic acid-inducible gene (RIG)-I-like recep-
tors (RLRs), and absent in melanoma 2 (AIM2)-like receptors
(ALRs) (91, 92). PRRs are commonly expressed by cells of the
innate immune system such as monocytes, macrophages, dendritic
cells (DCs), neutrophils, and epithelial cells, as well as cells of the
adaptive immune system (93).
Toll-like receptors and CLRs scan the extracellular milieu and
endosomal compartments for pathogen-associated molecular pat-
terns (PAMPs), which are highly conserved microbial structures
that are essential for microbial survival (94), while intracellular
PRRs, including NLRs, RLRs, and ALRs, cooperate to provide
cytosolic surveillance (92, 93).
In H. pylori infection, the first physical–chemical barriers for
the pathogen are the mucus layer,gastric epithelial cells, autophagy,
and PRRs (TLRs, NLRs, CLRs, and RLRs) (Figure 2).
TOLL-LIKE RECEPTORS AND HELICOBACTER
PYLORI -RELATED GASTRIC CANCER
TOLL-LIKE RECEPTORS RECOGNITION OF HELICOBACTER PYLORI
The involvement of the TLR signaling pathway in infectious,
autoimmune, and inflammatory diseases is well accepted (95).
During H. pylori infection, TLRs on gastric epithelial and immune
cells recognize diverse PAMPs such as flagellin/unknown PAMP
(TLR5), unmethylated CpG motifs (TLR9), and lipopolysaccha-
ride (LPS) (TLR4 and TLR2).
TLR4 was initially identified as the potential signaling receptor
for H. pylori LPS on gastric epithelial cells (96–99). After forming
a complex with the LPS-binding protein (LBP), LPS interacts with
the monocyte differentiation antigen CD14 (CD14), and subse-
quently with the myeloid differentiation protein-2 (MD-2) (100).
Together with TLR4, this complex induces the TLR4-mediated
MyD88-dependent signal transduction pathway, which leads to
the rapid activation of transcription factors, mainly NF-κB, and
cytokines such as TNF-α, IL-1β, IL-6, and IL-12 (95). On the other
hand, stimulation of TLR4 by LPS also facilitates the activation
of a MyD88-independent pathway that activates IFN-regulatory
factor (IRF) 3 and involves the late phase of NF-κB activation,
both of which lead to the production of IFN-β and the expres-
sion of IFN-inducible genes (101, 102). In addition to LPS, the
H. pylori secretory protein HP0175, through its ability to bind
to TLR4, was shown to transactivate the epidermal growth fac-
tor receptor (EGFR) and stimulate the EGFR-dependent vascular
endothelial growth factor production in the GC cell line AGS,
which have been linked to H. pylori-associated gastroduodenal
diseases, ulcerogenesis, and carcinogenesis (103).
Although early studies concluded that TLR4 is the first innate
immune response against H. pylori (104, 105), later studies sug-
gested that TLR4 had a limited role, given that H. pylori LPS
appeared to bind poorly to LBP, resulting in it being inefficiently
transferred to CD14 (106). Consequently, recent studies address-
ing the role of other TLRs during H. pylori infection, have found
TLR2 to be the initial barrier against H. pylori infection (107–112).
A potential explanation for these inter-study differences in relation
to the TLRs response to H. pylori might be attributed to cell type
(i.e., epithelial versus immune cells), origin of the cell studied (i.e.,
peritoneal versus bone marrow derived macrophages), and the
type of inflammatory response measured (i.e., type of cytokines),
and thus, currently any conclusions regarding the role of TLR4
must be treated with caution.
In contrast, there is strong evidence supporting an important
role for TLR2 in H. pylori infection, with both animal and cell
culture experiments suggesting that TLR2 ligands (LPS or other)
exist in H. pylori and related Helicobacter species (112–114), and
that TLR2 may be involved in the innate immune sensing of these
bacteria by epithelial cells (113). Furthermore, an interesting pub-
lication by Smith et al. (115) showed that H. pylori LPS functions as
a classic TLR2 ligand and induces a discrete pattern of chemokine
expression in epithelial cells, which involves modulation of the
expression of the signaling protein tribbles 3 (TRIB3), a molecule
implicated in the regulation of NF-κB.
Yet, the most likely scenario is that both TLR4 and TLR2 are
involved in the early immune response against H. pylori as has
been demonstrated by a number of investigators (116–118). For
example, Obonyo et al. (116) showed that both TLR2 and TLR4
were crucial signaling receptors for H. pylori activation of the host
immune response leading to the secretion of cytokines. Further,
Yokota et al. (118) not only showed that H. pylori LPS was ini-
tially targeted by TLR2 as described by others, but, for the first
time, showed that this TLR2 activation leads to cell proliferation
and TLR4 expression via the MEK1/2-ERK1/2 pathway. The final
outcome of this signaling pathway is increased proliferation of
gastric epithelial cells and the instauration of a strong inflamma-
tory reaction. Once this response is instaurated, H. pylori could
then enhance inflammatory reactions mediated by TLR4 agonists
such as other bacterial LPS, which would also contribute to gastric
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FIGURE 2 | Pattern-recognition receptors involvement in Helicobacter
pylori infection. H. pylori is recognized by the Toll-like receptors (TLRs)
(TLR2, TLR4, TLR5, and TLR9), NOD-like receptors (NLRs) (NOD1, NOD2,
NLRP3, and possibly, NLRP12 and NLRX1), RIG-I like receptors (RLRs) (RIG-I
and possibly, MDA-5), and C-type lectin receptors (CLRs) (DC-SIGN). TLR4
poorly recognizes H. pylori lipopolysaccharide (LPS) to generate
pro-inflammatory cytokines (e.g., IL-1α, IL-1β, IL-6, IL-8, IL-10, and TNF-α) and
interferons (IFNs) through the myeloid differentiation primary response gene
88 (MyD88)-dependent and -independent pathways, respectively. TLR2
recognizes H. pylori LPS/peptigoglycan/unknown pathogen-associated
molecular pattern (PAMP) while TLR5 poorly recognizes H. pylori flagella and
TLR9 recognizes H. pylori DNA (unmethylated CpG motifs). H. pylori
recognition by these three TLRs leads to nuclear factor-κB (NF-κB) activation.
NOD1 and NOD2 recognize H. pylori peptidoglycan-derived peptides
[γ-d-glutamyl-meso-diaminopimelic acid (iE-DAP) and muramyl dipeptide
(MDP)], leading to the activation of both transcription factors NF-κB and
activator protein (AP)-1. The NLRP3 inflammasome, comprising NLRP3,
apoptosis-associated speck-like protein containing a CARD (ASC) and
caspase-1, recognizes a yet unknown H. pylori PAMP and/or
damage-associated molecular pattern (DAMP), and through caspase-1
cleavage, leads to the maturation and secretion of interleukin (IL)-1β and IL-18.
NLRX1 and NLRP12, two known negative regulators of NF-κB, appear to be
significantly down-regulated during H. pylori infection in vitro, however, their
exact role during H. pylori infection remains unclear. RIG-I recognizes H. pylori
5′-triphosphorylated RNA (5′-PRNA) while MDA-5 possibly recognizes H.
pylori dsRNA. The dendritic cell-specific intercellular adhesion molecule-3
grabbing non-integrin (DC-SIGN) recognizes H. pylori fucosylated ligands and
this interaction appears to counteract the pro-inflammatory immune response
to H. pylori. Only one generic cell type depicting all TLRs, NLRs, RLRs, and
CLRs involved in H. pylori recognition is shown here for simplicity. MAL,
MyD88 adaptor-like protein, also named TIRAP; TRAM, translocating
chain-associating membrane protein; TRIF, TIR domain containing adaptor
inducing interferon-beta protein; TBK-1, TANK-binding kinase 1; IRF3,
IFN-regulatory factor 3; TRAF6, TNF receptor-associated factor 6; IRAK,
interleukin 1 receptor-associated kinase; RAS, proto-oncogene ras; c-RAF,
proto-oncogene protein ras; RIP2, receptor-interacting
serine/threonine-protein kinase 2, also known as RICK; CARD9, caspase
activation and recruitment domain; MD-2, myeloid differentiation protein-2;
ILs: interleukins. Names in orange correspond to molecules with a probable
but not established role in the host response to H. pylori.
inflammation and subsequent carcinogenesis (118). Further, the
heat-shock protein 60, an immune-potent antigen of H. pylori,
has been shown to activate NF-κB and induce IL-8 production
through TLR2 and TLR4 pathways in gastric epithelial cells, a
phenomenon that is likely to contribute to the development of
gastric inflammation caused by H. pylori infection (117).
In addition, TLR9 appears to play an important role in
H. pylori recognition. Interestingly, Rad et al. (112) identified
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TLR9-mediated recognition of H. pylori DNA as a main H. pylori-
induced intracellular TLR signaling pathway in DCs. Further,
a study using a murine model of H. pylori infection has sug-
gested that TLR9 signaling is involved in the suppression of H.
pylori-induced gastritis in the early phase of infection via down-
regulation of Th1-type cytokines modulated by IFN-α (119). In
addition, a recent study has shown that the gastric epithelia of chil-
dren respond to H. pylori infection by increasing the expression of
TLR2, TLR4, TLR5, and TLR9, as well as the cytokines IL-8, IL-10,
and TNF-α (120).
Although TLR5 interaction with H. pylori induces only weak
receptor activation (121), TLR5 has been involved in the inflam-
matory response to H. pylori. An interesting publication by Smith
et al. (107), using HEK293 cells transfected with specific TLR
expression constructs and MKN45 cells expressing dominant neg-
ative versions of TLR2, TLR4, and TLR5, which block the activity
of wild-type forms of these receptors, has demonstrated that live
H. pylori induces NF-κB activation and chemokine gene expres-
sion due to ligation of TLR2 and TLR5. A further study that aimed
to explore the involvement of TLR2 and TLR5 in THP-1 cells and
HEK293 cell lines (stably transfected with TLR2 or TLR5) during
H. pylori infection, has indicated that H. pylori-induced expression
of TLR2 and TLR5 can qualitatively shift cag PAI-dependent to
cag PAI-independent pro-inflammatory signaling pathways with
possible impact on the outcome of H. pylori-associated diseases
(122). Given the established TLR5 evasion of α and ε Proteobac-
teria including H. pylori (123), the TLR5-mediated inflammatory
responses during H. pylori infection described by Smith et al. (107)
and Kumar Pachathundikandi et al. (122) are likely to be flagellin-
independent, and therefore, a still unknown H. pylori factor might
be responsible for this.
The importance of TLRs recognition during H. pylori infection
and GC development is further supported by the acquired char-
acteristics that enable H. pylori to survive in the human stomach
and cause chronic inflammation. For example, H. pylori LPS is
characterized by a modification of the lipid A component of LPS
that makes it less pro-inflammatory (124) and has been reported
to exhibit a 1000-fold reduction in bioactivity as compared to
Escherichia coli LPS (125). Also, the flagellin of this bacterium
has been shown to be poorly recognized due to modifications
in the TLR5 recognition site of the N-terminal D1 domain of
flagellin (123).
TOLL-LIKE RECEPTORS AND GASTRIC CARCINOGENESIS
While TLR2, TLR4, TLR5, and TLR9 appear to be important for
H. pylori recognition, their role in the evolution of gastritis to
more advanced lesions remains unclear. Interestingly, Schmausser
et al. (126) showed that TLR9 was not detectable in intestinal
metaplasia or dysplasia and was only focally detected in 6 out
of 22 gastric carcinomas, while TLR4 and TLR5 were strongly
expressed by gastric carcinomas. Consistently, a study by Pimentel-
Nunes et al. (127) showed a statistically significant trend for a
progressive increase of TLR2, TLR4, and TLR5 expression from
normal mucosa to gastric dysplasia (mean expression in normal
mucosa: 0.1, gastritis: 1.0, metaplasia: 2.2, and dysplasia: 2.8, P-
value <0.01), with dysplasia presenting more than 90% positive
epithelial cells showing strong expression (2.8, 95% CI: 2.7–3). In
addition, these authors showed a significant trend for decrease in
TOLLIP and PPARγ, two TLR signaling pathway inhibitors, which
was associated with increasing levels of CDX-2, a marker for ade-
nocarcinoma, from normal mucosa to carcinoma (P-value<0.05)
(128). Fernandez-Garcia et al. (129) have also reported increased
expression of TLR3, TLR4, and TLR9 in GC, and furthermore,
these authors noted that TLR3 expression by cancer cells was sig-
nificantly associated with a poor overall survival in patients with
resectable tumors, which lead them to suggest that TLR3 might be
an indicator of tumor aggressiveness. Similarly, Yakut et al. (130)
investigating the association between serum IL-1β, TLR4 levels,
pepsinogen I and II, gastrin 17, vascular endothelial growth fac-
tor, and H. pylori CagA status in patients with a range of gastric
precancerous lesions, concluded that serum TLR4 levels could be
used as a biomarker to differentiate individuals presenting with
dysplasia from those with other gastric precancerous lesions, the
mean TLR4 level in patients with dysplasia (0.56± 0.098 ng/mL)
being significantly higher than in patients with H. pylori posi-
tive chronic non-atrophic gastritis (0.10± 0.15 ng/mL), chronic
atrophic gastritis (0.06± 0.07 ng/mL), and intestinal metaplasia
(0.12± 0.18 ng/mL). Furthermore, while TLRs have been shown
to be expressed at the apical and basolateral pole of both nor-
mal gastric epithelial cells and in H. pylori gastritis, in metaplasia,
dysplastic, and neoplastic epithelial cells all TLRs are expressed
diffusely and homogeneously throughout the cytoplasm, with
no apparent polarization, which may suggest an increased acti-
vation of these diffusely over-expressed receptors during gastric
carcinogenesis (126, 128).
In recent years, TLRs have been associated with tumor devel-
opment and progression processes including cell proliferation,
epithelial–mesenchymal transition, angiogenesis, metastasis, and
immunosuppression. Interestingly, Chochi et al. (104) not only
showed that H. pylori augmented the growth of GC via the
LPS-TLR4 pathway but also found that this bacterium attenu-
ated the antitumor activity and IFN-γ-mediated cellular immu-
nity of human mononuclear cells. In addition, Song et al. (131)
have suggested that flagellin-activated TLR5 enhances the pro-
liferation of GC cells through an ERK-dependent pathway. Fur-
thermore, Tye et al. (132) have proposed a novel role for TLR2
in promoting gastric tumorigenesis independent of inflamma-
tion, whereby up-regulation of TLR2 within epithelial tumor
cells, rather than infiltrating inflammatory cells, by the uncon-
trolled activation of the oncogenic transcription factor STAT3,
promoted gastric tumor cell proliferation, and survival via up-
regulation of anti-apoptotic genes [e.g., BCL2-related protein A1
(BCL2A1),baculoviral IAP repeat containing 3 (BIRC3), and B-cell
CLL/lymphoma 3 (BCL3)]. Further, two processes that facilitate
carcinogenesis and involve TLRs have recently been described by
Li et al. (133). Using LPS-treated CD14-knockdown GC cells, these
authors showed that CD14, an important co-receptor in the TLR4
complex, promotes tumor cell epithelial–mesenchymal transition
and invasion through TNF-α (133).
In addition, the expression of tumor-associated molecules
known to be important in gastric carcinogenesis has been linked
to the activation of the TLR signaling pathway. For example,
prostaglandin-endoperoxide synthase 2 (PTGS2), which is also
termed cyclooxygenase 2 (COX2), a key enzyme that catalyzes
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the conversion of arachidonic acid to prostaglandins, has been
shown to play a pivotal role in gastric inflammation and carcino-
genesis (134). For example, a study by Chang et al. (108), using
clinical H. pylori isolates, has shown that H. pylori acts through
TLR2/TLR9 to activate both the PI-PLCγ/PKCα/c-Src/IKKα/β
and NIK/IKKα/β pathways, resulting in the phosphorylation and
degradation of IκBα, which in turn leads to the stimulation of
NF-κB and the expression of PTGS2.
Further, as compared with normal cells, cancer cells are more
metabolically active and generate more reactive oxygen species
(ROS), which affects cell survival. Several studies have suggested
that ROS can act as secondary messengers and control a range
of signaling cascades, leading to sustained proliferation of cancer
cells (135, 136). In the context of gastric carcinogenesis, H. pylori-
infected gastric epithelial cells have been shown to generate ROS
(137). Interestingly, Yuan et al. (138) recently suggested that TLR4
expression in GC correlated with tumor stage and that activation
of TLR4 contributed to GC cell proliferation via mitochondrial
ROS production through up-regulation of phosphorylated Akt
and NF-κB p65 activation and nuclear translocation.
However, the involvement of TLRs in GC might be more
complex than initially suspected as TLRs not only recognize anti-
genic determinants of viruses, bacteria, protozoa, and fungi, but
are also involved in the detection of damage-associated molecu-
lar patterns (DAMPs) (e.g., extracellular adenosine triphosphate,
hyaluran, extracellular glucose, monosodium urate crystals) (139).
Release of DAMPs, which are especially targeted by TLR2 and
TLR4 (140–145) during cancer progression may cause chronic
inflammation leading to down-regulation of the ζ chain of the
T-cell and NK cell activating receptors [for comprehensive infor-
mation on this topic see the review by Baniyash et al. (146)], which
entails T-cell and NK cell dysfunction, a phenomenon observed in
some malignancies such as GC (147, 148), colon (149), prostate
(150), cervical (151), and pancreatic cancer (152). In addition to
immunosuppression, DAMPS appear to facilitate other processes
during gastric carcinogenesis. For example, Wu et al. (153) have
recently showed that hyaluronan, derived from malignant cells,
induced long-lived tumor-associated neutrophils and subsequent
malignant cell migration in gastric carcinomas via a TLR4/PI3K
interaction.
Collectively, TLRs might be involved in both gastric carcino-
genesis mediated by H. pylori infection (a tumor-promoting con-
sequence of inflammatory responses) and in GC perpetuation
associated with immunosuppression (active evasion by cancer
cells from attack and elimination by immune cells) and increased
metastasis.
GENETIC POLYMORPHISMS INVOLVED IN THE TOLL-LIKE RECEPTOR
SIGNALING PATHWAY AND GASTRIC CANCER
In recent years, a number of investigations have attempted
to establish the relationship between polymorphisms in mol-
ecules of the TLR signaling pathway and risk of GC. Recent
studies, conducted in several populations, have shown associa-
tions between the polymorphisms TLR1 rs5743618 (Ile602Ser)
(154), TLR2 −196 to −174del (155–158), TLR2 rs3804099 (157),
TLR4 rs4986790 (Asp299Gly) (155, 157, 159), TLR4 rs4986791
(Thr399Ile) (160), TLR4 rs10116253 (161), TLR4 rs10983755
(162), TLR4 rs11536889 (+3725G/C) (155), TLR4 rs1927911
(161), TLR5 rs5744174 (158), TLR9 rs187084 (−1486 T/C) (163),
and CD14 rs2569190 (−260 C/T) (155, 164–167), and risk of
GC development in an ethnic-specific manner (Table 1). In addi-
tion, three polymorphisms located in the TLR4 mRNA promoter
region (sites −2081,−2026, and −1601) and TLR4 Thr135Ala at
the leucine-rich repeat (LRR), have been associated with poorly
differentiated GC (168, 169).
Interestingly, some of these polymorphisms including TLR4
Asp299Gly (159, 184), TLR4 Thr399Ile (184, 185), TLR4
rs10759932 (186), CD14-260 C/T (187), and TLR2 −196 to
−174del (157), appear to be involved in the biological continuum
that results in intestinal-type GC as they have also been associated
with gastric precancerous lesions (Table 2).
Given that some authors have failed to show specific associ-
ations between polymorphisms in the TLR signaling pathway,
especially in TLR2, TLR4, and CD14, and gastric precancerous
lesions/GC (157, 160, 162, 164, 172, 174–178, 180–183, 185, 188,
189), we performed the first global meta-analysis to assess the
role of TLR2, TLR4, and CD14 polymorphisms in gastric carcino-
genesis (155), in an attempt to clarify the limited and current
conflicting evidence, and to establish the true impact of the TLR
signaling pathway in GC. Our meta-analysis, which included 18
case–control studies conducted in Caucasian, Asian, and Latin
American populations, showed that TLR4 Asp299Gly was a defin-
itive risk factor for GC in Western populations (pooled OR: 1.87,
95% CI: 1.31–2.65). In addition, there was a potential associa-
tion between TLR2 −196 to −174 and GC in Japanese (pooled
OR: 1.18, 95% CI: 0.96–1.45) (155). Interestingly, a recent meta-
analysis on TLR2 −196 to−174 and the risk of GC, conducted by
Cheng et al. (190), failed to reproduce the findings in our meta-
analysis, however, their stratification by ethnicity analyses included
subjects from both Japan and China, which might explain the
different outcomes. A further meta-analysis conducted by Chen
et al. (191) that included 21 case–control studies showed an over-
all increased risk of GC in individuals harboring TLR4 Asp299Gly
(Allele analysis, OR: 1.84, 95% CI: 1.41–2.39) and TLR4 Thr399Ile
(Allele analysis, OR: 1.97, 95% CI: 1.22–3.18). Consistently, in
stratified analyses by ethnicity, these authors only found an asso-
ciation between TLR4 Asp299Gly (Allele analysis, OR: 1.90, 95%
CI: 1.43–2.51) and TLR4 Thr399Ile (Allele analysis, OR: 2.84,
95% CI: 1.56–5.15) in Caucasian individuals (191). Further, Zhao
et al. (192) in an updated version of a meta-analysis that was
initially conducted by Zhang et al. (193), on the risk of TLR4
polymorphisms and risk of cancer in general, found a significant
association with GC after stratifying by cancer type (OR: 2.00,
95% CI: 1.53–2.62). In addition, Zou et al. (194), through a meta-
analysis that included 10 case–control studies, not only found that
TLR4 Asp299Gly was associated with GC (OR: 1.87, 95% CI: 1.44–
2.44), especially non-cardia GC (OR: 2.03, 95% CI: 1.51–2.72), but
also gastric precancerous lesions (OR: 2.47, 95% CI: 1.57–3.88),
especially in H. pylori-infected individuals (OR: 3.43, 95% CI:
1.92–6.13).
Given limited evidence regarding the association between poly-
morphisms in other molecules of the TLR signaling pathway and
the risk of GC, and the fact that 42% of cases of GC worldwide
occur in the Chinese population, we conducted a case–control
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Table 1 | Genetic polymorphisms in theToll-like receptor signalling pathway that have been studied in relation to gastric cancer (170).
Gene Polymorphism Reference Population GC subtype Total
sample
size
OR, 95% CIa
TLR1 rs5743618 (Ile602Ser) Yang et al. (154) German NS 284b OR: 0.40, 95% CI: 0.22–0.72
TLR2 −196 to −174del Castaño-Rodríguez et al. (170) Chinese Non-cardia 310 OR: 1.17, 95% CI: 0.81–1.71
de Oliveira et al. (157) Brazilian Non-cardia 440 OR: 2.32, 95% CI: 1.56–3.46
Zeng et al. (158) Chinese NS 744 OR: 0.66, 95% CI: 0.48–0.90
Hishida et al. (172) Japanese NS 1680 OR: 1.17, 95% CI: 0.79–1.73c
Tahara et al. (156) Japanese Non-cardia 744 OR: 6.06, 95% CI: 1.86–19.72
rs3804099 de Oliveira et al. (157) Brazilian Non-cardia 440 OR: 2.32, 95% CI: 1.56–3.46
rs3804100 Castaño-Rodríguez et al. (170) Chinese Non-cardia 310 OR: 3.16, 95% CI: 1.38–7.24
TLR4 rs4986790 (Asp299Gly) Qadri et al. (174) Indian NS 330 OR: 1.15, 95% CI: 0.66–2.03
de Oliveira et al. (157) Brazilian Non-cardia 440 OR: 2.01, 95% CI: 1.06–3.81
Schmidt et al. (175) Chinese Non-cardia 222 OR: 0.23, 95% CI: 0.03–1.81
Santini et al. (160) Italian NS 322 OR: 0.97, 95% CI: 0.37–1.14
Trejo de la O (176) Mexican NS 182 OR: 2.70, 95% CI: 0.36–10.70
Hold et al. (159) Caucasiand Non-cardia 731 OR: 2.50, 95% CI: 1.60–4.00
Hold et al. (159) Caucasiane Cardia and non-cardia 395 OR: 2.10, 95% CI: 1.10–4.20
Garza-Gonzalez et al. (177) Mexican Non-cardia 314 OR: 1.00, 95% CI: 0.30–2.80
rs4986791 (Thr399Ile) Qadri et al. (174) Indian NS 330 OR: 1.39, 95% CI: 0.70–2.78
de Oliveira et al. (157) Brazilian Non-cardia 440 OR: 1.81, 95% CI: 0.64–5.15
Santini et al. (160) Italian NS 322 OR: 3.62, 95% CI: 1.27–6.01
Trejo de la O (176) Mexican NS 263 OR: 1.40, 95% CI: 0.36–5.38
Garza-Gonzalez et al. (177) Mexican Non-cardia 314 OR: 0.25, 95% CI: 0.01–1.80
rs10116253 Castaño-Rodríguez et al. (170) Chinese Non-cardia 310 OR: 0.58, 95% CI: 0.34–1.00
Huang et al. (161) Chinese NS 511 OR: 0.33, 95% CI: 0.18–0.60
rs10759931 Castaño-Rodríguez et al. (170) Chinese Non-cardia 310 OR: 0.56, 95% CI: 0.33–0.97
rs10759932 Castaño-Rodríguez et al. (170) Chinese Non-cardia 310 OR: 0.59, 95% CI: 0.34–1.04
Huang et al. (178) Chinese Cardia and non-cardia 1962 OR: 1.03, 95% CI: 0.74–1.45
rs10983755 Kim et al. (179) Korean Non-cardia 974 OR: 1.41, 95% CI: 1.01–1.97
rs11536889 Castaño-Rodríguez et al. (170) Chinese Non-cardia 310 OR: 3.58, 95% CI: 1.20–10.65
Kupcinskas et al. (180) Caucasianf NS 349 OR: 1.03, 95% CI: 0.62–1.71
Hishida et al. (181) Japanese NS 1639 OR: 1.04, 95% CI: 0.66–1.63
rs1927911 Castaño-Rodríguez et al. (170) Chinese Non-cardia 310 OR: 0.47, 95% CI: 0.27–0.82
Huang et al. (161) Chinese NS 511 OR: 0.37, 95% CI: 0.21–0.70
rs2149356 Castaño-Rodríguez et al. (170) Chinese Non-cardia 310 OR: 0.59, 95% CI: 0.34–1.02
TLR5 rs5744174 Zeng et al. (158) Chinese NS 744 OR: 1.43, 95% CI: 1.03–1.97
TLR9 rs187084 (−1486 T/C) Wang et al. (163) Chinese Cardia and non-cardia 628 OR: 1.63, 95% CI: 1.01–2.64
CD14 rs2569190 (−260 C/T) Castaño-Rodríguez et al. (170) Chinese Non-cardia 310 OR: 0.72, 95% CI: 0.5–1.02
Companioni et al. (164) Caucasiang Cardia and non-cardia 1649 OR: 0.92, 95% CI: 0.77–1.09
Li et al. (133) Tibetan NS 462 OR: 2.16, 95% CI: 1.34–3.47
Kim et al. (179) Korean Non-cardia 974 OR: 0.97, 95% CI: 0.77–1.23h
Hold et al. (182) Caucasiand Non-cardia 716 OR: 1.00, 95% CI: 0.70–1.40
Hold et al. (182) Caucasian e Cardia and non-cardia 395 OR: 0.80, 95% CI: 0.50–1.30
Tahara et al. (166) Japanese Non-cardia 237 OR: 0.31, 95% CI: 0.12–0.78
Zhao et al. (167) Chinese NS 940 OR: 1.95, 95% CI: 1.20–3.16
Wu et al. (183) Chinese Non-cardia 414 OR: 0.98, 95% CI: 0.75–1.29
(Continued)
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Table 1 | Continued
Gene Polymorphism Reference Population GC subtype Total
sample
size
OR, 95% CIa
MD-2 rs11465996 Castaño-Rodríguez et al. (170) Chinese Non-cardia 310 OR: 4.83, 95% CI: 2.02–11.57
rs16938755 Castaño-Rodríguez et al. (170) Chinese Non-cardia 310 OR: 3.80, 95% CI: 1.48–9.77
LBP rs2232578 Castaño-Rodríguez et al. (170) Chinese Non-cardia 310 OR: 3.07, 95% CI: 1.24–7.59
TIRAP rs7932766 Castaño-Rodríguez et al. (170) Chinese Non-cardia 310 OR: 6.04, 95% CI: 1.89–19.36
GC, gastric cancer; OR, odds ratio; CI, confidence intervals; NS, not specified.
aOR and 95% CI correspond to allele or genotype analysis, depending on available information in the article.
bThe control group included individuals with high risk gastritis (pangastritis, corpus-predominant gastritis with or without the presence of gastric atrophy, and intestinal
metaplasia in either antrum or corpus).
cCompared to gastric atrophy controls.
dThe study population is from Poland.
eThe study population is from the United States. No significant association was found with cardia GC.
fSubjects from Germany, Lithuania and Latvia.
gSubjects from France, Italy, Spain, United Kingdom, The Netherlands, Greece, Germany, Sweden, Denmark and Norway.
hEffect size for intestinal-type GC, diffuse type: OR: 0.99, 95% CI: 0.78–1.26.
study comprising 310 ethnic Chinese individuals (87 non-cardia
GC cases and 223 controls with functional dyspepsia), in which
25 polymorphisms involved in the TLR signaling pathway were
investigated (170). Seven polymorphisms showed significant asso-
ciations with GC (TLR4 rs11536889, TLR4 rs10759931, TLR4
rs1927911, TLR4 rs10116253, TLR4 rs10759932, TLR4 rs2149356,
and CD14 −260 C/T). In multivariate analyses, TLR4 rs11536889
remained a risk factor for GC even after adjustment (OR: 3.58,
95% CI: 1.20–10.65). Further, TLR4 rs10759932 decreased the
risk of H. pylori infection (OR: 0.59, 95% CI: 0.41–0.86) (170).
Strikingly, statistical analyses assessing the joint effect of H. pylori
and the selected polymorphisms revealed that H. pylori-infected
individuals harboring TLR2 rs3804100, TLR2 −196 to −174del,
TLR4 rs11536889, MD-2 rs11465996, MD-2 rs16938755, LBP
rs2232578, and TIRAP rs7932766 were at most risk of developing
GC (Table 1) (170).
The functional relevance of a number of these polymorphisms
has already been established. For example, two polymorphisms
in TLR4, Asp299Gly, and Thr399Ile, have been shown to dis-
rupt the normal structure of the extracellular domain of TLR4,
and thus, as a result, may reduce responsiveness to H. pylori by
diminishing the binding affinity of the bacterial ligands (195). In
addition, the TLR4 rs11536889 polymorphism, which is located in
the center of the 2818-bp TLR4 3′ untranslated region (UTR), has
recently been shown by Sato et al. (196) to contribute to the trans-
lational regulation of TLR4, possibly by binding to microRNAs.
Further, these authors elegantly demonstrated that subjects har-
boring TLR4 rs11536889 exhibited higher levels of TLR4 receptors
on monocytes and secreted higher levels of IL-8 in response to LPS
(196). In addition, TLR4 rs10759932 has been shown to decrease
the expression of forkhead box protein P3 (FOXP3), the most spe-
cific marker for natural regulatory T (Treg) cells (197). FOXP3+
Treg cells, which suppress the immune response of antigen-specific
T cells, have been demonstrated to play a key role in immuno-
logic tolerance (198). Notably, recent studies have not only shown
that in vivo depletion of FOXP3+ Treg cells in H. pylori-infected
mice leads to increased gastric inflammation and reduced bacter-
ial colonization (199), but also recruitment of FOXP3+ Treg cells
is increased in H. pylori-related human disorders including gas-
tritis (200, 201), duodenal ulcer (202), and GC (200, 203, 204),
suggesting that FOXP3+ Treg cells might contribute to lifelong
persistence of H. pylori infection. Also, TLR1 rs5743618 appears
to impair the surface expression of TLR1 of NK cells and NK cells-
derived IFN-γ production (154). Further, TLR2 −196 to −174
has been associated with decreased transcriptional activity of TLR2
(205, 206). Similarly, it has been demonstrated that TLR9 rs187084
down-regulates TLR9 expression (207).
Further, CD14 has been shown to activate macrophages/
monocytes to release Th1-type cytokines including IL-12, thus,
establishing the chronic inflammation stimulated by H. pylori
infection (208–210). A Th1 predominant response has been exten-
sively associated with the pathogenesis of H. pylori-related gastric
disease (211–213). Currently, however, controversy exists regard-
ing the influence of CD14 −260 on expression of soluble CD14
(sCD14). According to a number of studies, the CD14 −260 T
allele is believed to increase sCD14 production and therefore,
serum sCD14 levels (214–217). In contrast, it has been reported
that elevated sCD14 levels are associated with H. pylori infec-
tion, especially in subjects with the CD14 −260 CC genotype
(167). Alternatively, others have argued that this polymorphism
has no effect on transcription (218). Since the evidence to date
is conflicting, more functional studies are required to clarify this
issue.
Overall, it is clear that genetic variability in genes of the TLR
signaling pathway plays an important role in GC pathogene-
sis. Investigations of polymorphisms in different molecules of
this pathway among different populations could provide novel
insights into targeted treatment in genetically susceptible individ-
uals, and thus, improve primary and secondary prevention of H.
pylori-related GC in high risk populations.
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Table 2 | Genetic polymorphisms in theToll-like receptor signalling pathway that have been studied in relation to gastric precancerous lesions.
Reference Journal Population Precancerous
lesion
Cases Controls Total Polymorphism OR (95% CI)a
Fan et al. (186) Human Immunology Chinese IM 193 312 505 TLR4 Asp299Gly 0.89 (0.46–1.72)
TLR4 Thr399Ile 1.01 (0.33–3.14)
TLR4 rs10759932 0.42 (0.29–0.62)
Dysplasia 140 312 452 TLR4 Asp299Gly 0.81 (0.38–1.73)
TLR4 Thr399Ile 0.83 (0.22–3.19)
TLR4 rs10759932 0.62 (0.41–0.93)
de Oliveira et al. (157) Digestive Diseases and
Science
Brazilian CG 229 240 469 TLR4 Asp299Gly 1.60 (0.84–3.06)
TLR4 Thr399Ile 1.08 (0.35–3.39)
TLR2 −196–174 del 1.52 (1.01–2.29)
Kupcinskas et al. (180) BMC Medical Genetics Caucasian CG, AG and IM 222 238 460 TLR4 rs11536889 0.94 (0.62–1.44)
Zeng et al. (158) Cancer Epidemiology,
Biomarkers and
Prevention
Chinese IM 496 496 992 TLR2 −196–174 del 0.99 (0.65–1.52)
TLR5 rs5744174 1.55 (0.78–3.11)
Dysplasia 350 496 846 TLR2 −196–174 del 0.99 (0.73–1.35)
TLR5 rs5744174 1.73 (0.84–3.55)
Rigoli et al. (184) Anti-Cancer Research Caucasian CG 60b 87 147 TLR4 Asp299Gly 4.80 (1.93–12.35)
TLR4 Thr399Ile 3.73 (1.36–10.14)
Hishida et al. (172) Gastric Cancer Japanese AGc 494 443 937 TLR2 −196–174 del 1.08 (0.70–1.67)
Hishida et al. (181) Helicobacter Japanese AGc 536 1056 1592 TLR4 rs11536889 1.20 (0.76–1.89)
Murphy et al. (188) European Journal of
Gastroenterology and
Hepatology
Caucasian CG 91 96 187 TLR4 Asp299Gly 1.12 (0.49–2.52)
90 91 181 TLR4 Thr399Ile 0.97 (0.44–2.11)
IM 63 96 159 TLR4 Asp299Gly 1.33 (0.49–3.59)
62 91 153 TLR4 Thr399Ile 0.99 (0.38–2.63)
Hofner et al. (189) Helicobacter Caucasian CG 136d 75 211 TLR4 Asp299Gly 1.25 (0.53–2.95)
TLR4 Thr399Ile 0.94 (0.39–2.24)
Achyut et al. (185) Human Immunology Indian AG 68 200 268 TLR4 Asp299Gly 1.50 (0.55–3.82)
TLR4 Thr399Ile 4.2 (1.13–15.73)
IM 50 200 250 TLR4 Asp299Gly 1.10 (0.32–3.50)
TLR4 Thr399Ile 4.7 (1.52–14.63)
Hold et al. (159) Gastroenterology Caucasian AG 45e 100 145 TLR4 Asp299Gly 11.0 (2.50–48.0)
Kato et al. (187) Digestive Diseases and
Science
Venezuelan AG 289 1033 1322 CD14 −260 C/T 1.17 (0.81–1.70)
IM 543 1033 1575 CD14 −260 C/T 1.45 (1.06–1.99)
Dysplasia 118 1033 1151 CD14 −260 C/T 1.44 (0.82–2.55)
CG, chronic gastritis; AG, atrophic gastritis; IM, intestinal metaplasia; OR, odds ratio; CI, confidence intervals.
aOR and 95% CI correspond to allele or genotype analysis, depending on available information in the article.
bOnly individuals with corpus-predominant chronic gastritis were included in the meta-analysis (individual presenting antrum-predominant gastritis were excluded).
cAnalyses including only H. pylori seropositive individuals.
dOnly patients with chronic gastritis were included in the meta-analysis (patients presenting duodenal ulcer were excluded).
eCases were GC patients’ relatives with gastric atrophy and infected with H. pylori from a Scotland population.
NOD-LIKE RECEPTORS AND HELICOBACTER
PYLORI -RELATED GASTRIC CANCER
NOD-LIKE RECEPTORS RECOGNITION OF HELICOBACTER PYLORI
The NLR family not only recognizes PAMPs but also DAMPs in the
cytoplasm (93). The NLRs characteristic structure includes a cen-
tral nucleotide-binding and oligomerization (NACHT) domain
that is present in all NLR family members, a C-terminal LRRs
and an N-terminal caspase recruitment (CARD) or pyrin (PYD)
domain.
Based on phylogenetic analysis of NACHT domains, the NLR
family has been shown to comprise three subfamilies: (1) the
NOD family which includes NOD1-2, NOD 3 (NLRC3), NOD4
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(NLRC5), NOD5 (NLRX1), and CIITA, (2) the NLRPs including
NLRP1-14 (also known as NALPs), and (3) the IPAF subfamily,
which consists of IPAF (NLRC4) and NAIP (93).
The NACHT domain belongs to a family of P-loop NTPases
known as the signal transduction ATPases with numerous domains
(STAND) (219). This domain permits activation of the signal-
ing complex via adenosine ATP-dependent oligomerization (94).
NACHT domain oligomerization is essential for the activation of
NLRs, forming high molecular weight complexes, probably hexa-
mers or heptamers that characterize inflammasomes (molecular
complexes involved in the activation of inflammatory caspases for
the maturation and secretion of IL-1β, IL-18, and possibly IL-
33) and NOD signalosomes (complexes that are assembled upon
oligomerization of NOD1 or NOD2 and lead to NF-κB activa-
tion through the receptor-interacting protein-2) (94). CARD and
PYD are death domains that mediate homotypic protein–protein
interactions for down-stream signaling (93, 94). These domains
are characterized by six α helices that form trimers or dimers with
other members of the same subfamily (94). The third domain, the
LRR region, has been implicated in ligand sensing and autoreg-
ulation of not only NLRs but TLRs (93, 94). The LRR is formed
by tandem repeats of a structural unit consisting of a β strand
and an α helix and is composed of 20–30 amino acids that form a
horse-shoe shaped structure rich in the hydrophobic amino acid
leucine (220). The NLRPs LRR gene is made up of tandem repeats
of exons of exactly 171 nucleotides, which encode one central
LRR and two halves of the neighboring LRRs (221). This partic-
ular modular organization possibly allows extensive alternative
splicing of the LRR region leading to maximum variability in
the ligand-sensing unit (94). However, a recent publication by
Tenthorey et al. (222) analyzing a panel of 43 chimeric NAIPs,
showed that LRR was unnecessary for NAIP/NLRC4 inflamma-
some ligand specificity, leading them to propose a model in which
NAIP activation is instead triggered by ligand binding to NACHT-
associated helical domains. This recent evidence suggests that
the ligand-sensing function of the LRR domain in NLRs, which
has been supported primarily by analogy to the well-established
ligand-sensing function of the LRR region in TLRs, needs to be
re-examined.
The most widely studied NLRs during H. pylori infec-
tion are NOD1 and NOD2, which are expressed in epithe-
lial and antigen-presenting cells, and are known to specifically
recognize peptidoglycan-derived peptides (γ-d-glutamyl-meso-
diaminopimelic acid and muramyl dipeptide, respectively). An
early study, attempting to determine the mechanism whereby H.
pylori delivers peptidoglycan to cytosolic host NOD1, demon-
strated that H. pylori peptidoglycan is delivered to the host
cell via a type IV secretion system (223). More recently, Hut-
ton et al. (224) showed, for the first time, that cholesterol-rich
microdomains called lipid rafts, were important for the type IV
secretion system-dependent peptidoglycan delivery and subse-
quent NF-κB activation and IL-8 production, mediated by NOD1.
Interestingly, Kaparakis et al. (225) reported a novel mechanism
in Gram-negative bacteria, including H. pylori, for the delivery of
peptidoglycan to cytosolic NOD1 in host cells that involves outer
membrane vesicles that enter epithelial cells through lipid rafts.
In addition, Necchi et al. (226) demonstrated the formation of
a particle-rich cytoplasmic structure (PaCS) in H. pylori-infected
human gastric epithelium having metaplastic or dysplastic foci,
where VacA, CagA, urease, outer membrane proteins, NOD1
receptor, ubiquitin-activating enzyme E1, polyubiquitinated pro-
teins, proteasome components, and potentially oncogenic proteins
like SHP-2 and ERKs colocalized, inferring that this structure
is likely to modulate inflammatory and proliferative responses
during H. pylori infection.
The recent finding that NF-κB and AP-1 complexes can be
physically translocated to the nucleus in response to NOD1 acti-
vation has led to the view that NOD1 is likely to be essential for
the induction of both NF-κB and AP-1 activation during H. pylori
infection (227). A number of studies have shown up-regulation
of NOD1 expression in diverse human cell lines challenged with
H. pylori in a cag PAI-dependent manner (228–230). Further, H.
pylori cag PAI-positive strains have recently been shown to activate
the NOD1 pathway through two components of the IFN-γ signal-
ing pathway,STAT1 and IRF1 (228). Similarly, expression of NOD2
was shown to significantly sensitize HEK293 cells to H. pylori-
induced NF-κB activation in a cag PAI-dependent manner (231).
Further, NOD2, but not NOD1, seems to be required for induction
of pro-IL-1β and NLRP3 in H. pylori-infected DCs (232).
A limited number of studies have assessed the interaction
between NLRPs and other inflammasome-associated molecules,
and H. pylori. NLRPs represent the largest NLR subfamily (14
genes have been identified in humans) and are believed to be
the scaffolding proteins of inflammasomes (221, 233). NLRPs
interact and recruit the adaptor apoptosis-associated speck-like
protein (ASC) via PYD-PYD interaction (94). ASC (also known
as PYCARD), a key component required for inflammasome for-
mation, is formed by an N-terminal PYD and a C-terminal CARD
(234, 235). This interaction leads to the recruitment of caspase-1,
an intracellular aspartate specific cysteine protease, which subse-
quently leads to the maturation and release of pro-inflammatory
cytokines (236).
An early study by Tomita et al. (237) demonstrated that in
H. pylori positive patients antral IL-18 mRNA expression was
increased as compared with H. pylori negative patients, however,
mature IL-18 protein and active caspase-1 were found to be present
in both infected and non-infected gastric mucosa. Interestingly,
in the following year, Potthoff et al. (238) reported activation of
caspase-3, -8, and -9, but not caspase-1, in AGS cells challenged
with H. pylori. However, this finding is in contrast with subse-
quent studies, which have demonstrated an important role for
NLRPs and inflammasome-related molecules in H. pylori infec-
tion. For example, Basak et al. (96) demonstrated that H. pylori
LPS could activate caspase-1 through Rac1/PAK1 signaling, and
that activated caspase-1 played a role in LPS-induced IL-1β matu-
ration (96). Further, ASC-deficient mice challenged with H. pylori
have been shown to exhibit higher bacterial loads and signifi-
cantly lower levels of gastritis, when compared with wild-type
mice, and were incapable of producing IL-1β or IL-18 and pro-
duced less INF-γ in response to H. pylori infection (239). Later,
Hitzler et al. (240) showed in both cultured DCs and in vivo that
H. pylori infection activates caspase-1, leading to IL-1β/IL-18 pro-
cessing and secretion. Consistently, three studies, using human GC
cell lines, gastric tissue, and murine models, confirmed increased
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expression of caspase-1, IL-1β, and IL-18 in H. pylori-infected
cells (171, 241, 242). Further, Jiang et al. (243), also using a murine
model, have reported the expression of NLRP3 inflammasome-
related molecules as well as serum IL-1β, IL-18, and IL-33 levels to
be significantly increased in H. pylori-infected mice. More recently,
a study by Kim et al. (232) has shown that secretion of IL-1β by
DCs infected with H. pylori requires TLR2, NOD2, and the NLRP3
inflammasome.
Given that little is known about the role of NLRPs, inflamma-
somes, or other molecules involved in the NLR signaling pathways
in response to H. pylori infection, we recently assessed the gene
expression of 84 different molecules involved in the NLR signal-
ing pathways, through quantitative real-time PCR, using THP-
1-derived macrophages infected with two strains of H. pylori,
GC026 (GC) and 26695 (gastritis) (173). Our gene expression
analyses showed five genes encoding NLRs to be significantly
regulated in H. pylori-challenged cells (NLRC4, NLRC5, NLRP9,
NLRP12, and NLRX1) (173). Interestingly, NLRP12 and NLRX1,
two known NF-κB negative regulators, were markedly down-
regulated, while NFKB1 and several NF-κB target genes encod-
ing pro-inflammatory cytokines (IFNB1, IL12A, IL-12B, IL6, and
TNF), chemokines (CXCL1, CXCL2, and CCL5) and molecules
involved in carcinogenesis (PTGS2 and BIRC3) were markedly up-
regulated, in THP-1 cells infected with a highly virulent H. pylori
strain isolated from a GC patient. These findings highlight the
relevance of the NLR signaling pathways in gastric carcinogenesis
and its close interaction with NF-κB (173).
Overall, current evidence clearly shows that, in response to H.
pylori, members of the NOD and NLRP subfamilies are critical for
generating mature pro-inflammatory cytokines/chemokines that
are crucial for Th1 responses and lead to H. pylori-related gastric
disorders.
NOD-LIKE RECEPTORS AND GASTRIC CARCINOGENESIS
The role of the NLR signaling pathways in the biological contin-
uum that characterizes GC remains relatively unexplored as a very
limited number of studies have addressed this issue. For exam-
ple, Allison et al. (228) have shown that NOD1 expression was
significantly increased in human gastric biopsies displaying severe
gastritis, when compared with those without gastritis, as well as in
gastric tumor tissues, as compared with paired non-tumor tissues.
In contrast, Jee et al. (244), who analyzed human GC tissues and
GC cell lines, showed that a significant decrease in the expression
of caspase-1 was associated with poor survival and was inversely
correlated with p53 expression.
Given the reported interaction of H. pylori with NLRs and the
importance of this in the development of gastric inflammation and
subsequent carcinogenesis, as well as the production of DAMPs
during tumor formation (245), further comprehensive studies of
the functional relevance of NLRs activation during chronic gastri-
tis, atrophic gastritis, intestinal metaplasia, dysplasia, and GC are
clearly warranted.
GENETIC POLYMORPHISMS INVOLVED IN THE NOD-LIKE RECEPTOR
SIGNALING PATHWAY AND GASTRIC CANCER
The majority of studies examining the association between poly-
morphisms involved in the NLR signaling pathways and the risk
of GC have focused on NOD1 and NOD2 polymorphisms. Stud-
ies, conducted in a number of populations, have investigated
the association between the polymorphisms NOD1 rs2907749
(246), NOD1 rs7789045 (246), NOD1 rs2075820 (E266K) (179,
247), NOD1 rs5743336 (180), NOD2 rs7205423 (246), NOD2
rs7202124 (164), NOD2 rs2111235 (164), NOD2 rs5743289 (164),
NOD2 rs2066842 (P268S) (248, 249), NOD2 rs2066844 (R702W)
(250), NOD2 rs2066845 (G908R) (184), and NOD2 rs2066847
(L1007insC) (184, 250), and risk of gastric precancerous lesions
and GC (Table 3). Further, a recent meta-analysis by Liu et al.
(251) that included six case–control studies has shown consistent
associations between NOD2 R702W, G908R, and L1007insC, and
risk of GC.
Given the documented relevance of other NLRs in H. pylori
infection and related GC, and that polymorphisms in genes such
as NLRP3 (252–255) and CARD8 (255, 256) have been associated
with inflammatory gastrointestinal disorders, we addressed, for the
first time, the association between 51 polymorphisms in six genes
(NLRP3, NLRP12, NLRX1, CASP1, ASC, and CARD8) involved in
the NLR signaling pathways and risk of GC in a high risk Chi-
nese population (173). In this study, we found novel associations
between CARD8 rs11672725 and the risk of GC, and NLRP12
rs2866112 and the risk of H. pylori infection (Table 3). Fur-
ther, we showed that the concomitant presence of polymorphisms
involved in the NLR signaling pathways (CARD8, NLRP3, CASP1,
and NLRP12) and H. pylori infection dramatically increased the
risk of GC in Chinese (Table 3) (173).
The functional relevance of a number of these polymorphisms
has been examined. For example, the introduction of NOD2
R702W, a polymorphism located in the LRR of NOD2, into the
HEK293 cell line, resulted in abrogation of H. pylori-induced
activation of NF-κB signaling (231). Further, Maeda et al. (257)
observed increased NF-κB activation in response to muramyl
dipeptide in mice harboring a NOD2 mutation that is homolo-
gous to NOD2 rs5743293 (3020insC) in humans. However, it is
worth noting that the conclusions described by Maeda et al. (257)
must be interpreted with care given that the authors subsequently
found a duplication of the 3’ end of the wild-type Nod2 locus,
including exon 11, which was targeted by the mutation, and there-
fore, they are currently working to recreate a mutant strain without
such a duplication.
Given that investigation of the role of polymorphisms involved
in the NLR signaling pathways in GC is a relatively recent field
of research, further studies are required to assess the associa-
tion between these polymorphisms and GC in a range of human
populations, especially those at high risk of GC.
OTHER PATTERN-RECOGNITION RECEPTORS AND HELICOBACTER
PYLORI -RELATED GASTRIC CANCER
A further two PRR subfamilies, RLRs and CLRs, have been studied
in relation to H. pylori infection and gastric carcinogenesis. It is
well known that RLRs (RIG-I, MDA-5, and LGP2) induce type
I IFN in response to different RNA viruses, however, investiga-
tion on the role of RIG-I-like receptors in the recognition of RNA
derived from intracellular bacteria is very limited. Interestingly,
a study by Rad et al. (112), which used mice lacking simultane-
ously up to four different TLRs, apart from identifying TLR2 and
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Table 3 | Genetic polymorphisms in the NOD-like receptor signalling pathway that have been studied in relation to gastric precancerous lesions
and gastric cancer.
Reference Journal Population Gastric lesion Study
sample
size
Polymorphism OR (95% CI)a
Castaño-Rodríguez
et al. (173)
PLoS One Chinese GC 310 CARD8 rs11672725 4.80 (1.39–16.58)
CARD8 rs10405717 2.46 (1.04–5.84)b
CARD8 rs2043211 0.19 (0.058–0.63)b
NLRP3 rs12079994 4.15 (1.70–10.12)b
NLRP3 rs3806265 3.33 (1.09–10.13)b
NLRP3 rs4612666 4.03 (1.15–14.16)b
NLRP12 rs2866112 4.73 (2.06–10.88)b
NLRP12 rs4419163 2.42 (1.12–5.23)b
NLRX1 rs10790286 4.00 (1.66–9.61)b
CASP1 rs2282659 4.65 (1.67–12.95)b
CASP1 rs530537 4.65 (1.67–12.95)b
CASP1 rs61751523 4.56 (1.57–13.28)b
Companioni
et al. (164)
International Journal of
Cancer
Caucasian GC 1649 NOD2 rs7202124 0.74 (0.61–0.89)
NOD2 rs2111235 0.77 (0.64–0.93)
NOD2 rs5743289 3.76 (1.33–10.63)c
Kim et al. (179) Helicobacter Korean IM 412 NOD1 rs2075820 (E266K) 1.0 (0.74–1.34)d
Wang et al. (246) World Journal of
Gastroenterology
Chinese GC 456 NOD1 rs2907749 0.50 (0.26–0.95)
NOD1 rs7789045 2.14 (1.20–3.82)
NOD2 rs7205423 0.82 (0.39–1.72)
Kupcinskas et al.
(180)
BMC Medical Genetics Caucasian GC 574 NOD1 rs5743336 1.01 (0.48–2.16)
CG, AG and IM 0.78 (0.40–1.49)
Rigoli et al. (184) Anti-cancer Research Caucasian CG 147 NOD2 G908R 5.18 (1.65–16.09)
NOD2 L1007insC 3.66 (1.13–11.80)
Kara et al. (247) Clinical and
Experimental Medicine
Turkish AG 150 NOD1 rs2075820 (E266K) 13.35 (5.12–34.82)
IM 2.71 (1.26–5.80)
Hnatyszyn et al.
(248)
Experimental and
Molecular Pathology
Caucasian CG, AG, IM and GC 244 NOD2 rs2066842 (P268S) 2.2 (1.40–3.30)
Angeletti
et al. (250)
Human Immunology Caucasian GC 326 NOD2 rs2066844 (R702W) 4.1 (1.75–9.42)d
NOD2 rs2066845 (G908R) 0.56 (0.17–1.65)d
NOD2 rs2066847 (L1007insC) 16.10 (3.83–67.81)d
Wex et al. (249) Anti-cancer Research Caucasian GC 324 NOD2 rs2066842 (P268S) 1.5 (1.05–2.17)
NOD2 rs2066844 (R702W) 1.3 (0.66–2.55)
Hofner et al. (189) Helicobacter Caucasian CG 211 NOD1 rs2075820 (E266K) 1.06 (0.66–1.73)
GC, gastric cancer; IM, intestinal metaplasia; AG, atrophic gastritis; GC, chronic gastritis; OR, odds ratio; CI, confidence intervals.
aOR and 95% CI correspond to allele or genotype analysis, depending on available information in the article.
bOnly in H. pylori-infected individuals.
cSignificant only in non-cardia H. pylori CagA negative individuals.
dResults obtained through a Fisher’s exact probability test (two-tailed P-values) conducted in the current review using the information provided in the original article.
TLR9 to be important H. pylori recognizing PRRs, also showed
that H. pylori 5′-triphosphorylated RNA can be sensed by RIG-I
and can contribute to the TLR-independent type I IFN response
to this bacteria in DCs. Further, Tatsuta et al. (258) have recently
shown that MDA-5 expression was significantly increased in the
human gastric antral mucosa of H. pylori-infected individuals. In
addition, these authors showed that increased MDA-5 levels corre-
lated with atrophy and intestinal metaplasia in the corpus of these
individuals (258).
C-type lectin receptors bind to carbohydrates (mannose- or
fucose-containing glycans) present on pathogens to tailor immune
responses to viruses, bacteria, and fungi. DC-specific intercellular
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FIGURE 3 | Pattern-recognition receptors and gastric carcinogenesis.
Based on this comprehensive literature review, we propose a synergistic
interaction between pattern-recognition receptors (PRRs) and Helicobacter
pylori in gastric carcinogenesis. The association between PRRs and risk of
GC might be a continuum commencing in childhood. Individuals harboring
polymorphisms in PRRs could not only be more susceptible to acquisition
of H. pylori in childhood but also would present deregulation of NF-κB in
gastric epithelial and immune cells, and subsequent uncontrolled
production of cytokines/chemokines, due to dysfunctional PRRs. This in
turn would impact upon the direction and magnitude of the chronic
inflammatory response to H. pylori. As H. pylori, the dominant bacterium
in the stomach, gradually disappears upon the development of gastric
atrophy, it is plausible that other microbial species might bloom in its
absence and perpetuate local inflammation through further PRRs
activation. Over time, the combination of these events would facilitate a
number of features that promote gastric cancer development including cell
proliferation, epithelial–mesenchymal transition, angiogenesis, metastasis,
and immunosuppression.
adhesion molecule-3-grabbing non-integrin (DC-SIGN) is a CLR
expressed on the surface of both macrophages and DCs. Inter-
estingly, it has been shown that H. pylori harbors fucosylated
ligands that can be recognized by DC-SIGN (259). Further, H.
pylori DC-SIGN ligands appear to actively dissociate the signal-
ing complex down-stream of DC-SIGN (KSR1–CNK–Raf-1) to
suppress pro-inflammatory cytokine production (259). In addi-
tion, H. pylori LPS Lewis blood-group antigens can bind to
DC-SIGN in a fucose or galactose-dependent manner (260, 261)
and this interaction appears to inhibit a Th1 response in DCs
(262). It has also been demonstrated that H. pylori-induced IL-
10 production in monocyte-derived DCs is significantly sup-
pressed by the addition of anti-DC-SIGN, TLR2, or TLR4 anti-
bodies, either alone or in combination, before H. pylori stim-
ulation (263). Further, in vitro and in vivo experiments have
shown that the expression of DC-SIGN is significantly higher
in H. pylori-infected individuals as compared with that in their
uninfected counterparts (264, 265).
To date, no studies have been conducted to determine
the association between genetic polymorphisms involved in
the RLR and CLR signaling pathways and GC, however,
Kutikhin and Yuzhalin (266) have comprehensively analyzed
the oncogenic potential of both RLRs and CLRs, suggest-
ing that future oncogenomic investigations should focus on
polymorphisms in MRC1 (rs1926736, rs2478577, rs2437257,
and rs691005), CD209 (rs2287886, rs735239, rs4804803, and
rs735240), CLEC7A (rs16910526), and RIG-I (rs36055726,
rs11795404, and rs10813831).
Given the limited but consistent current evidence suggesting a
role of RLRs and CLRs in H. pylori infection, and the documented
interaction between these signaling pathways and other important
PRRs in GC such as TLRs (267, 268) and NLRs (269, 270), further
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studies assessing the implications of RLRs and CLRs in H. pylori-
related inflammation and subsequent carcinogenesis need to be
conducted.
PATTERN-RECOGNITION RECEPTORS AS THERAPEUTICS
TARGETS IN GASTRIC CANCER
Pattern-recognition receptors are increasingly recognized as
important players in immunotherapy as PRRs-specific agonists
elicit a potent immune response to cancers, allergic diseases, and
chronic viral infections, while reducing the risk of an uncontrolled
and detrimental systemic inflammatory response (for comprehen-
sive information on this topic refer to the reviews by Hedayat et al.
(271) and Paul-Clark et al. (272).
In the context of gastric carcinogenesis, Tye et al. (132), using
a GC murine model (gp130F/F) displaying elevated gastric TLR2
expression levels, have elegantly shown that genetic and antibody-
mediated therapeutic targeting of TLR2 leads to a substantial
reduction in stomach size and overall tumor burden, including
the number of gastric tumors. A further example is presented in
the study by Gradisar et al. (273), which suggested that MD-2 is
one of the important targets of curcumin (diferuloylmethane),
the main component of the spice turmeric (Curcuma longa) that
is widely used for gastric disorders in the Indian subcontinent,
in its suppression of the innate immune response to bacterial
infection. Furthermore, curcumin was recently shown to polar-
ize myeloid-derived suppressor cells, extracted from a human GC
xenograft mouse model, toward a M1-like phenotype with an
increased expression of CCR7 and decreased expression of the
CLR dectin 1, being both observed in vivo (tumor tissue) and
in vitro (splenic myeloid-derived suppressor cells from tumor-
bearing mice) (274). In addition, a study by Yang et al. (171)
demonstrated that the combination of catechins and sialic acid is
effective in suppressing the inflammatory responses mediated by
the inflammasome/caspase-1 signaling pathway in gastric epithe-
lial cells during H. pylori infection. Also, poly(I:C), an agonist
of TLR3 and RLRs, has been shown to have a pro-apoptotic
effect in vitro, and has significantly inhibited xenograft growth
of human GC in a mouse model, through up-regulation of RLRs
(RIG-I, MDA-5, and LGP2) as well as an increased expression
of Bcl-2 family members, suggesting that it may be a promising
chemotherapeutic agent against GC (275).
Given that modulation of PRRs has been proven to be relevant
in gastric carcinogenesis through diverse mechanisms, including
suppression of H. pylori-induced inflammation and enhancement
of cancer cell apoptosis, this approach should be considered a new
and promising angle of immunotherapy in GC.
CONCLUSION
In conclusion, abundant evidence supports the pivotal role of
PRRs in gastric carcinogenesis as these receptors of the innate
immune system, including TLRs, NLRs, CLRs, and RLRs, have
been shown to recognize diverse components of H. pylori, the
major risk factor of GC. In addition, PRRs are also involved
in gastric carcinogenesis per se as these receptors are known to
exert tumor-promoting functions (cell proliferation, epithelial–
mesenchymal transition, angiogenesis, and metastasis) as well
as immunosuppression during cancer. Given that host genetic
variability in the TLR and NLR signaling pathways are known
to be associated with an increased risk of H. pylori infection, the
development of gastric precancerous lesions and GC, this knowl-
edge has the potential to allow better prevention of GC through
selective treatment and surveillance of individuals harboring high
risk genetic profiles. Finally, given that PRRs are increasingly
being used as a target for immunotherapy against both cancer
and infectious diseases, the established relevance of PRRs in H.
pylori infection and GC, could suggest that PRR agonists and/or
antagonists may potentially improve the outcome of GC. Based
on the extensive evidence presented in the current review, we pro-
pose a synergistic interaction between PRRs and H. pylori, which
over time, could facilitate the sequence of events that character-
izes GC development including inflammation, atrophy, intestinal
metaplasia, dysplasia, and finally, GC (Figure 3).
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